Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Once-buzzy OData continues to move forward at Microsoft, with new .NET 10-aligned tooling previews and an ODataX proposal aimed at easing adoption while preserving the protocol's enterprise-strength ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback